Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study

Maria Bibi Lyng; Anne-Vibeke Lænkholm; Qihua Tan; Werner Vach; Karina Hedelund Gravgaard; Ann Knoop; Henrik Jørn Ditzel

doi:10.1371/journal.pone.0054078

Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study

Maria Bibi Lyng
, Anne-Vibeke Lænkholm
, Qihua Tan
, Werner Vach
, Karina Hedelund Gravgaard
, Ann Knoop
, Henrik Jørn Ditzel

Afdeling for Patologi

12 Citationer (Scopus)

Abstract

Tamoxifen significantly improves outcome for estrogen receptor-positive (ER+) breast cancer, but the 15-year recurrence rate remains 30%. The aim of this study was to identify gene profiles that accurately predicted the outcome of ER+ breast cancer patients who received adjuvant Tamoxifen mono-therapy.

Originalsprog	Engelsk
Tidsskrift	P L o S One
Vol/bind	8
Udgave nummer	1
Sider (fra-til)	e54078
ISSN	1932-6203
DOI	https://doi.org/10.1371/journal.pone.0054078
Status	Udgivet - 2013

Adgang til dokumentet

10.1371/journal.pone.0054078

Citationsformater

@article{3f8a6fe81eac4a828f71314d56ba8182,

title = "Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study",

abstract = "Tamoxifen significantly improves outcome for estrogen receptor-positive (ER+) breast cancer, but the 15-year recurrence rate remains 30\%. The aim of this study was to identify gene profiles that accurately predicted the outcome of ER+ breast cancer patients who received adjuvant Tamoxifen mono-therapy.",

keywords = "Aged, Breast Neoplasms, Cyclin-Dependent Kinase Inhibitor p21, Female, Humans, Middle Aged, Polymerase Chain Reaction, Proto-Oncogene Proteins c-bcl-2, Receptors, Estrogen, Tamoxifen",

author = "Lyng, \{Maria Bibi\} and Anne-Vibeke L{\ae}nkholm and Qihua Tan and Werner Vach and Gravgaard, \{Karina Hedelund\} and Ann Knoop and Ditzel, \{Henrik J{\o}rn\}",

year = "2013",

doi = "10.1371/journal.pone.0054078",

language = "English",

volume = "8",

pages = "e54078",

journal = "P L o S One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "1",

}

TY - JOUR

T1 - Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients

T2 - a DBCG study

AU - Lyng, Maria Bibi

AU - Lænkholm, Anne-Vibeke

AU - Tan, Qihua

AU - Vach, Werner

AU - Gravgaard, Karina Hedelund

AU - Knoop, Ann

AU - Ditzel, Henrik Jørn

PY - 2013

Y1 - 2013

N2 - Tamoxifen significantly improves outcome for estrogen receptor-positive (ER+) breast cancer, but the 15-year recurrence rate remains 30%. The aim of this study was to identify gene profiles that accurately predicted the outcome of ER+ breast cancer patients who received adjuvant Tamoxifen mono-therapy.

AB - Tamoxifen significantly improves outcome for estrogen receptor-positive (ER+) breast cancer, but the 15-year recurrence rate remains 30%. The aim of this study was to identify gene profiles that accurately predicted the outcome of ER+ breast cancer patients who received adjuvant Tamoxifen mono-therapy.

KW - Aged

KW - Breast Neoplasms

KW - Cyclin-Dependent Kinase Inhibitor p21

KW - Female

KW - Humans

KW - Middle Aged

KW - Polymerase Chain Reaction

KW - Proto-Oncogene Proteins c-bcl-2

KW - Receptors, Estrogen

KW - Tamoxifen

U2 - 10.1371/journal.pone.0054078

DO - 10.1371/journal.pone.0054078

M3 - Journal article

C2 - 23342080

SN - 1932-6203

VL - 8

SP - e54078

JO - P L o S One

JF - P L o S One

IS - 1

ER -

Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater